Cardiovascular Diabetology

Article	Citations
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness an	485
The association between index-year, average, and variability of the triglyceride-glucose index with health outcomes: more than a decade of follow-up in Tehran lipid and glucose study	372
Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) pros	258
Associations of combined polygenic risk score and glycemic status with atrial fibrillation, coronary artery disease and ischemic stroke	218
Dysregulation of long non-coding RNA gene expression pathways in monocytes of type 2 diabetes patients with cardiovascular disease	199
Sex differences and sex steroids influence on the presentation and severity of cardiovascular autonomic neuropathy of patients with type 1 diabetes	182
Dysregulation of hypoxia-inducible factor 1α in the sympathetic nervous system accelerates diabetic cardiomyopathy	175
Surgical treatment on infective endocarditis: impact of diabetes on mortality	175
Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes	174
Correction to: Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists	165
Association between triglyceride–glucose index and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study	153
Healthy longevity-associated protein improves cardiac function in murine models of cardiomyopathy with preserved ejection fraction	150
Proteinuria and the risk of Incident atrial fibrillation according to glycemic stages: a nationwide population-based cohort study	141
Obesity-induced mesenteric PVAT remodelling is sexually dimorphic, but not driven by ovarian hormones	126
Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT	122
Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes	119
Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics	118
Data-independent LC-MS/MS analysis of ME/CFS plasma reveals a dysregulated coagulation system, endothelial dysfunction, downregulation of complement machinery	112
Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation	109
Multi-modal characterisation of early-stage, subclinical cardiac deterioration in patients with type 2 diabetes	107
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis	107
BMI-based obesity classification misses children and adolescents with raised cardiometabolic risk due to increased adiposity	104
Impact of T2DM on right ventricular systolic dysfunction and interventricular interactions in patients with essential hypertension: evaluation using CMR tissue tracking	103
The atherogenic index of plasma and carotid atherosclerosis in a community population: a population-based cohort study in China	102
Nonlinear relationship between atherogenic index of plasma and the risk of prediabetes: a retrospective study based on Chinese adults	99

Longitudinal assessment of coronary plaque regression related to sodium–glucose cotransporter-2 inhibitor using coronary computed tomography angiography	99
Bone proteins are associated with cardiovascular risk according to the SCORE2-Diabetes algorithm	98
Impact of red cell distribution width and red cell distribution width/albumin ratio on all-cause mortality in patients with type 2 diabetes and foot ulcers: a retrospective cohort study	96
Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes	96
High triglyceride-glucose index and stress hyperglycemia ratio as predictors of adverse cardiac events in patients with coronary chronic total occlusion: a large-scale prospective cohort study	92
Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus	89
The triglyceride-glucose index predicts 1-year major adverse cardiovascular events in end-stage renal disease patients with coronary artery disease	89
Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes	88
Combined associations of visceral adipose tissue and adherence to a Mediterranean lifestyle with T2D and diabetic microvascular complications among individuals with prediabetes	88
In-hospital glycemic variability and all-cause mortality among patients hospitalized for acute heart failure	87
The triglyceride-glucose index is associated with atherosclerosis in patients with symptomatic coronary artery disease, regardless of diabetes mellitus and hyperlipidaemia	85
Investigating sex-specific associations of lipid traits with type 2 diabetes, glycemic traits and sex hormones using Mendelian randomization	84
Variability of risk factors and diabetes complications	83
Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study	83
Association between triglyceride–glucose index trajectories and radiofrequency ablation outcomes in patients with stage 3D atrial fibrillation	83
Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study	83
The association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study from MIMIC-IV database	81
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management	79
Association between the triglyceride glucose index and in-hospital and 1-year mortality in patients with chronic kidney disease and coronary artery disease in the intensive care unit	79
Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention	79
Association between non-insulin-based insulin resistance indices and cardiovascular events in patients undergoing percutaneous coronary intervention: a retrospective study	77
The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy	77
Comprehensive transcriptomics and metabolomics analyses reveal that hyperhomocysteinemia is a high risk factor for coronary artery disease in a chinese obese population aged 40–65: a prospective cross	76
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes	76
Association between triglyceride glucose-body mass index and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study	75
Ethnicity should be included as a risk factor for coronary artery calcium score	74
Predicting major adverse cardiac events in diabetes and chronic kidney disease: a machine learning study from the Silesia Diabetes-Heart Project	74
Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte	73
Deficiency of neutral cholesterol ester hydrolase 1 (NCEH1) impairs endothelial function in diet-induced diabetic mice	73
Triglyceride-glucose index is associated with a higher risk of stroke in a hypertensive population	72
Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial	69
The association between the triglyceride–glucose index and vulnerable plaques in patients with type 2 diabetes mellitus: insights from coronary computed tomography angiography	68
Preeclampsia as an independent predictor of atherosclerosis progression in women with type 1 diabetes: a 5-year prospective study	68
Sex differences in myocardial flow reserve among individuals with type 2 diabetes: insights from the DiaHeart study	66
Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes	65
Lower miR-21/ROS/HNE levels associate with lower glycemia after habit-intervention: DIAPASON study 1-year later	64
Plasma metabolite profile of legume consumption and future risk of type 2 diabetes and cardiovascular disease	63
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal eva	62
Correction to: Expression of the SARS‑CoV‑2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system	61
Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study	61
Prognostic value of long-term trajectories of depression for incident diabetes mellitus in patients with stable coronary heart disease	61
Correction: Higher HbA1c variability is associated with increased arterial stiffness in individuals with type 1 diabetes	61
Stress hyperglycemia ratio and in-hospital prognosis in non-surgical patients with heart failure and type 2 diabetes	61
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms	61
Association between C-reactive protein-triglyceride glucose index and stroke risk in different glycemic status: insights from the China Health and Retirement Longitudinal Study (CHARLS)	58
Advances in cardiac organoid research: implications for cardiovascular disease treatment	58
Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial	57
Plasma lipidic fingerprint associated with type 2 diabetes in patients with coronary heart disease: CORDIOPREV study	57
Association of temporal change in body mass index with sudden cardiac arrest in diabetes mellitus	57
Normal fasting triglyceride levels and incident type 2 diabetes in the general population	55

The synergistic effect of the triglyceride-glucose index and a body shape index on cardiovascular mortality: the construction of a novel cardiovascular risk marker	54
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease	54
Multi-trajectories of triglyceride-glucose index and lifestyle with Cardiovascular Disease: a cohort study	53
Temporal patterns of multi-morbidity in 570157 ischemic heart disease patients: a nationwide cohort study	53
Dual-trajectory of TyG levels and lifestyle scores and their associations with ischemic stroke in a non-diabetic population: a cohort study	53
Atherogenic index of plasma for non-diabetic, coronary artery disease patients after percutaneous coronary intervention: a prospective study of the long-term outcomes in China	53
MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics	52
Novel lipid indicators and the risk of type 2 diabetes mellitus among Chinese hypertensive patients: findings from the Guangzhou Heart Study	52
Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database	52
The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003–2018	52
Combined effect of skeletal muscle mass loss and elevated insulin resistance on heart failure risk in older adults: a community-based longitudinal cohort study	52
Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach	52
Association of the triglyceride glucose index with all-cause and cardiovascular mortality in a general population of Iranian adults	52
Joint association of the triglyceride–glucose index and stress hyperglycemia ratio with incidence and mortality risks of new-onset atrial fibrillation during sepsis: a retrospective cohort study	51
Clonal hematopoiesis of indeterminate potential and type 2 diabetes mellitus among patients with STEMI: from a prospective cohort study combing bidirectional Mendelian randomization	51
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study	51
Longitudinal economic burden of incident complications among metabolic syndrome populations	51
Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation	50
Rapid kidney function decline and increased risk of heart failure in patients with type 2 diabetes: findings from the ACCORD cohort	50
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease	50
Assessment of left atrioventricular coupling and left atrial function impairment in diabetes with and without hypertension using CMR feature tracking	49
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study	49
Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study	49
Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction: assessment with 3.0 T MRI feature tracking	49
Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic card	48
The association of triglyceride-glucose and triglyceride-glucose related indices with the risk of heart disease in a national cohort study	48
Monocytes perturbation implicated in the association of stress hyperglycemia with postoperative poor prognosis in non-diabetic patients with Stanford type-A acute aortic dissection	48
Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study	48
The predictive value of lesion-specific pericoronary fat attenuation index for major adverse cardiovascular events in patients with type 2 diabetes	48
Prognostic impacts of diabetes status and lipoprotein(a) levels in patients with ST-segment elevation myocardial infarction: a prospective cohort study	48
Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis	48
Estimated potassium intake and major adverse cardiovascular events in individuals with type 2 diabetes: a prospective cohort study with trans-ethnic validation	47
Joint assessment of abdominal obesity and non-traditional lipid parameters for primary prevention of cardiometabolic multimorbidity: insights from the China health and retirement longitudinal study 20	47
Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial	46
Non-coding RNA-mediated endothelial-to-mesenchymal transition in human diabetic cardiomyopathy, potential regulation by DNA methylation	46
SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis	46
Consultation rates in people with type 2 diabetes with and without vascular complications: a retrospective analysis of 141,328 adults in England	46
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management	45
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus	45
Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CS	45
Glycemic control and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: insight from ventricular remodeling using cardiac MRI	45
Diabetes does not increase in-hospital or short-term mortality in patients undergoing surgical repair for type A aortic dissection: insight from the national readmission database	45
Sex-specific associations of fat mass and muscle mass with cardiovascular disease risk factors in adults with type 2 diabetes living with overweight and obesity: secondary analysis of the Look AHEAD t	44
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes	44
Heart rate variability tests for diagnosing cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus in advanced stages of kidney disease	43
Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetes	43
Expanded response letter to “Hemodialysis dose and frequency should be considered in the subgroup analysis”	43
Circulating ANGPTL8 levels and risk of kidney function decline: Results from the 4C Study	43
Endothelial microRNAs in INOCA patients with diabetes mellitus	43
Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes	43
One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis	42
Effects of glycemic traits on left ventricular structure and function: a mendelian randomization study	42
Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study	41
Effects of diabetes mellitus on left ventricular function and deformation in patients with restrictive cardiomyopathies: a 3.0T CMR feature tracking study	41
ApoC-III proteoforms are associated with better lipid, inflammatory, and glucose profiles independent of total apoC-III	41
Predicting 28-day all-cause mortality in patients admitted to intensive care units with pre-existing chronic heart failure using the stress hyperglycemia ratio: a machine learning-driven retrospective	41
Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial	41
Body-weight variability and risk of cardiovascular outcomes in patients with type 1 diabetes: a retrospective observational analysis of data from the DCCT/EDIC population	41
Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study	41
GPR30-driven fatty acid oxidation targeted by ginsenoside Rd maintains mitochondrial redox homeostasis to restore vascular barrier in diabetic retinopathy	41
Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials	40
Predicting gestational diabetes mellitus risk at 11–13 weeks’ gestation: the role of extrachromosomal circular DNA	40
The additional impact of metabolic syndrome on left ventricular deformation and myocardial energetic efficiency impairment in ischemia with nonobstructive coronary arteries patients	40
Adipsin improves diabetic hindlimb ischemia through SERPINE1 dependent angiogenesis	39
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLE	39
Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study	39
Pathways from insulin resistance to incident cardiovascular disease: a Bayesian network analysis	39
Association of stress hyperglycemia ratio and poor long-term prognosis in patients with myocardial infarction with non-obstructive coronary arteries	38
Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study	38
Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio	38
Mitochondrial network remodeling of the diabetic heart: implications to ischemia related cardiac dysfunction	38
The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats	38
Independent association of thigh muscle fat density with vascular events in Korean adults	38
The association of hepatic steatosis and fibrosis with heart failure and mortality	38
Cardiovascular risk of metabolically healthy obesity in two european populations: Prevention potential from a metabolomic study	38
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study	37
Ion channel Piezo1 activation aggravates the endothelial dysfunction under a high glucose environment	37
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy	37
Association between the triglyceride–glucose index and severity of coronary artery disease	37
Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists	36

Triglyceride glucose index predicts long-term mortality and major adverse cardiovascular events in patients with type 2 diabetes	36
Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials	36
The right ventricular dysfunction and ventricular interdependence in patients with T2DM and aortic regurgitation: an assessment using CMR feature tracking	35
Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care	35
Correction to: Association between the triglyceride-glucose index and the risk of mortality among patients with chronic heart failure: results from a retrospective cohort study in China	35
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease	35
Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: populatio	35
The impact of prior exposure to hypoglycaemia on the inflammatory response to a subsequent hypoglycaemic episode	35
Altered RBC deformability in diabetes: clinical characteristics and RBC pathophysiology	35
Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes	35
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial	35
The neutrophil–lymphocyte ratio as a risk factor for all-cause and cardiovascular mortality among individuals with diabetes: evidence from the NHANES 2003–2016	35
Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study	34
Impact of mental disorders on the risk of atrial fibrillation in patients with diabetes mellitus: a nationwide population-based study	34
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study	34
High plasma renin activity associates with obesity-related diabetes and arterial hypertension, and predicts persistent hypertension after bariatric surgery	34
Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational study	34
Associations between glycated hemoglobin and the risks of incident cardiovascular diseases in patients with gout	34
Correction: Nut consumption is associated with a shift of the NMR lipoprotein subfraction profile to a less atherogenic pattern among older individuals at high CVD risk	34
Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study	33
Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease	33
Associations of genetic markers of diabetes mellitus with carotid atherosclerosis: a community-based case–control study	33
Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial	33
A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control	33
Associations of estimated glucose disposal rate with frailty progression: results from two prospective cohorts	32
ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling	32
Low-frequency variants in genes involved in glutamic acid metabolism and γ-glutamyl cycle and risk of coronary artery disease in type 2 diabetes	32
Multi-dimensional characterization of prediabetes in the Project Baseline Health Study	32
The association between TyG index and cardiovascular mortality is modified by antidiabetic or lipid-lowering agent: a prospective cohort study	32
Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank study	32
Association between triglyceride glucose index and arterial stiffness and coronary artery calcification: a systematic review and exposure-effect meta-analysis	31
Triglyceride-glucose index in the development of peripheral artery disease: findings from the Atherosclerosis Risk in Communities (ARIC) Study	31
Arterial stiffness in patients with type 1 diabetes and its comparison to cardiovascular risk evaluation tools	31
Contributions of elevated CRP, hyperglycaemia, and type 2 diabetes to cardiovascular risk in the general population: observational and Mendelian randomization studies	31
Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study	31
Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry	31
Insulin resistance quantified by estimated glucose disposal rate predicts cardiovascular disease incidence: a nationwide prospective cohort study	31
Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: “INSIST” study	31
Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes	31
The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease	30
Relationship between TyG index and the degree of coronary artery lesions in patients with H-type hypertension	30
Sex-related differences for uric acid in the prediction of cardiovascular events in essential hypertension. A population prospective study	30
Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation	30
Single-cell insights: pioneering an integrated atlas of chromatin accessibility and transcriptomic landscapes in diabetic cardiomyopathy	30
Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states	30
MiRNA-132/212 encapsulated by adipose tissue-derived exosomes worsen atherosclerosis progression	30
Association of triglyceride glucose index and triglyceride glucose-body mass index with sudden cardiac arrest in the general population	30
Bone marrow mesenchymal stem cell-derived extracellular vesicles alleviate diabetes-exacerbated atherosclerosis via AMPK/mTOR pathway-mediated autophagy-related macrophage polarization	30
Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study	30
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention	29
Long-term cardiovascular outcomes of biodegradable polymer drug eluting stents in patients with diabetes versus non-diabetes mellitus: a meta-analysis	29
Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study	29
The triglyceride-glucose index: a novel predictor of stroke and all-cause mortality in liver transplantation recipients	29
Obesity cardiomyopathy could contribute to sudden cardiac death: a Japanese epidemiological morphological study	29
Prognostic value of computed tomography-derived fractional flow reserve in patients with diabetes mellitus and unstable angina	29
Lifestyle factors and their relative contributions to longitudinal progression of cardio-renal-metabolic multimorbidity: a prospective cohort study	29
The additive effect of essential hypertension on coronary artery plaques in type 2 diabetes mellitus patients: a coronary computed tomography angiography study	29
Association of stress induced hyperglycemia with angiographic findings and clinical outcomes in patients with ST-elevation myocardial infarction	29
Triglyceride-glucose index correlates with the incidences and prognoses of cardiac arrest following acute myocardial infarction: data from two large-scale cohorts	29
Identification of plasma miR-4505, miR-4743-5p and miR-4750-3p as novel diagnostic biomarkers for coronary artery disease in patients with type 2 diabetes mellitus: a case-control study	28
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?	28
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes	28
Association of insulin use with LV remodeling and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: assessed by cardiac MRI	28
Association of diabetes mellitus with clinical outcomes in patients with different coronary artery stenosis	28
Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study	27
Glycemic control and cardiovascular outcomes in patients with diabetes and coronary artery disease according to triglyceride-glucose index: a large-scale cohort study	27
Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity	27
Basement membrane proteins in various arterial beds from individuals with and without type 2 diabetes mellitus: a proteome study	27
Triglyceride-glucose index predicts adverse cardiovascular events in patients with H-type hypertension combined with coronary heart disease: a retrospective cohort study	27
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial	27
Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts	27
Estimated glucose disposal rate outperforms other insulin resistance surrogates in predicting incident cardiovascular diseases in cardiovascular-kidney-metabolic syndrome stages 0–3 and the developmen	27
Prognostic value of triglyceride glucose index in population at high cardiovascular disease risk	27
Epicardial and liver fat implications in albuminuria: a retrospective study	27
Distribution and prognostic value of high-sensitivity cardiac troponin T and I across glycemic status: a population-based study	27
Exosomal microRNAs in diabetic heart disease	27
Assessment of subclinical LV myocardial dysfunction in T2DM patients with diabetic peripheral neuropathy: a cardiovascular magnetic resonance study	27
Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study	26
Association between the triglyceride-glucose index and subclinical left ventricular systolic dysfunction in obese patients	26
Probing erythrocytes as sensitive and reliable sensors of metabolic disturbances in the crosstalk between childhood obesity and insulin resistance: findings from an observational study, in vivo challe	26
Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients without diabetes mellitus after coronary artery bypass grafting: a multicenter retrospective cohort study	26
Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups	26
Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction	26
A molecular signature for the metabolic syndrome by urine metabolomics	26
Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes	26
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease	26
Associations of triglyceride glucose-body mass index with short-term mortality in critically ill patients with ischemic stroke	26
Real world data on cardiometabolic diseases in U.S. adults during the SARS-CoV-2 pandemic: a decentralized registry study	25
Triglyceride-glucose index: a novel evaluation tool for all-cause mortality in critically ill hemorrhagic stroke patients-a retrospective analysis of the MIMIC-IV database	25
Supra-additive effect of chronic inflammation and atherogenic dyslipidemia on developing type 2 diabetes among young adults: a prospective cohort study	25
Cardiomyocyte-specific NHE1 overexpression confers protection against myocardial infarction during hyperglycemia	25
Artificial sweeteners and risk of incident cardiovascular disease and mortality: evidence from UK Biobank	25
Low total osteocalcin levels are associated with all-cause and cardiovascular mortality among patients with type 2 diabetes: a real-world study	25
The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus	25
The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction	25